Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years
IntroductionAllogeneic hematopoietic cell transplantation (alloHCT) possessed direct cytotoxicity and graft-versus-multiple myeloma effect (GvMM). Growing trials have shown survival benefits of performing alloHCT in both newly diagnosed and relapsed MM.MethodsWe aimed to provide a comprehensive anal...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1341631/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849339341713702912 |
|---|---|
| author | Si Yu Lin Ke Jie Lu Xiao Na Zheng Jian Hou Ting Ting Liu |
| author_facet | Si Yu Lin Ke Jie Lu Xiao Na Zheng Jian Hou Ting Ting Liu |
| author_sort | Si Yu Lin |
| collection | DOAJ |
| description | IntroductionAllogeneic hematopoietic cell transplantation (alloHCT) possessed direct cytotoxicity and graft-versus-multiple myeloma effect (GvMM). Growing trials have shown survival benefits of performing alloHCT in both newly diagnosed and relapsed MM.MethodsWe aimed to provide a comprehensive analysis in the recent 10 years to verify the efficacy and survival outcome of alloHCT in MM patients. A total of 61 studies which provide data between 14/04/2013 and 14/04/2023 and a total of 15,294 data from MM patients who had undergone alloSCT were included in our study. The best response rates (CR, VGPR, PR) and survival outcomes (1-, 2-, 3-,5-, and 10-year OS, PFS, NRM) were assessed. We further conducted meta-analysis in the NDMM/frontline setting and RRMM/salvage setting independently.ResultsThe pooled estimate CR, VGPR, and PR rates were 0.45, 0.21, and 0.24, respectively. The pooled estimates of 1-, 2-, 3-, 5-, and 10-year OS were 0.69, 0.57, 0.45, 0.45, and 0.36, respectively; the pooled estimates of 1-, 2-, 3-, 5-, and 10-year PFS were 0.47, 0.35, 0.24, 0.25, and 0.28, respectively; and the pooled estimates of 1-, 2-, 3-, 5-, and 10-year NRM were 0.16, 0.21, 0.16, 0.20, and 0.15, respectively. In the NDMM/upfront setting, the pooled estimate CR rate was 0.54, and those for 5-year OS, PFS, and NRM were 0.69, 0.40, and 0.11, respectively. In a relapsed setting, the pooled estimate CR rate was 0.31, and those for 5-year OS, PFS, and NRM were 0.24, 0.10, and 0.15, respectively.DiscussionOur results showed constant OS, PFS, and NRM from the third year onwards till the 10th year, suggesting that alloSCT has sustained survival benefits. Good response rate and promising survival outcome were observed in the NDMM/ frontline setting.ConclusionAlthough comparing with other treatments, alloSCT had a lower response rate and poorer short-term survival outcome, long-term follow-up could reveal survival benefits of alloSCT in MM patients. |
| format | Article |
| id | doaj-art-2ec4f2603c0b481ca6b2b60eef267c6f |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-2ec4f2603c0b481ca6b2b60eef267c6f2025-08-20T03:44:10ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-07-011410.3389/fonc.2024.13416311341631Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 yearsSi Yu LinKe Jie LuXiao Na ZhengJian HouTing Ting LiuIntroductionAllogeneic hematopoietic cell transplantation (alloHCT) possessed direct cytotoxicity and graft-versus-multiple myeloma effect (GvMM). Growing trials have shown survival benefits of performing alloHCT in both newly diagnosed and relapsed MM.MethodsWe aimed to provide a comprehensive analysis in the recent 10 years to verify the efficacy and survival outcome of alloHCT in MM patients. A total of 61 studies which provide data between 14/04/2013 and 14/04/2023 and a total of 15,294 data from MM patients who had undergone alloSCT were included in our study. The best response rates (CR, VGPR, PR) and survival outcomes (1-, 2-, 3-,5-, and 10-year OS, PFS, NRM) were assessed. We further conducted meta-analysis in the NDMM/frontline setting and RRMM/salvage setting independently.ResultsThe pooled estimate CR, VGPR, and PR rates were 0.45, 0.21, and 0.24, respectively. The pooled estimates of 1-, 2-, 3-, 5-, and 10-year OS were 0.69, 0.57, 0.45, 0.45, and 0.36, respectively; the pooled estimates of 1-, 2-, 3-, 5-, and 10-year PFS were 0.47, 0.35, 0.24, 0.25, and 0.28, respectively; and the pooled estimates of 1-, 2-, 3-, 5-, and 10-year NRM were 0.16, 0.21, 0.16, 0.20, and 0.15, respectively. In the NDMM/upfront setting, the pooled estimate CR rate was 0.54, and those for 5-year OS, PFS, and NRM were 0.69, 0.40, and 0.11, respectively. In a relapsed setting, the pooled estimate CR rate was 0.31, and those for 5-year OS, PFS, and NRM were 0.24, 0.10, and 0.15, respectively.DiscussionOur results showed constant OS, PFS, and NRM from the third year onwards till the 10th year, suggesting that alloSCT has sustained survival benefits. Good response rate and promising survival outcome were observed in the NDMM/ frontline setting.ConclusionAlthough comparing with other treatments, alloSCT had a lower response rate and poorer short-term survival outcome, long-term follow-up could reveal survival benefits of alloSCT in MM patients.https://www.frontiersin.org/articles/10.3389/fonc.2024.1341631/fullmultiple myelomaallogeneic stem cell transplantationresponse ratesurvival outcomeOSPFS |
| spellingShingle | Si Yu Lin Ke Jie Lu Xiao Na Zheng Jian Hou Ting Ting Liu Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years Frontiers in Oncology multiple myeloma allogeneic stem cell transplantation response rate survival outcome OS PFS |
| title | Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years |
| title_full | Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years |
| title_fullStr | Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years |
| title_full_unstemmed | Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years |
| title_short | Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years |
| title_sort | efficacy and survival outcome of allogeneic stem cell transplantation in multiple myeloma meta analysis in the recent 10 years |
| topic | multiple myeloma allogeneic stem cell transplantation response rate survival outcome OS PFS |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1341631/full |
| work_keys_str_mv | AT siyulin efficacyandsurvivaloutcomeofallogeneicstemcelltransplantationinmultiplemyelomametaanalysisintherecent10years AT kejielu efficacyandsurvivaloutcomeofallogeneicstemcelltransplantationinmultiplemyelomametaanalysisintherecent10years AT xiaonazheng efficacyandsurvivaloutcomeofallogeneicstemcelltransplantationinmultiplemyelomametaanalysisintherecent10years AT jianhou efficacyandsurvivaloutcomeofallogeneicstemcelltransplantationinmultiplemyelomametaanalysisintherecent10years AT tingtingliu efficacyandsurvivaloutcomeofallogeneicstemcelltransplantationinmultiplemyelomametaanalysisintherecent10years |